Tvardi Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
/ 
Frequently asked questions
To buy Tvardi Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Tvardi Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Tvardi Therapeutics Inc. is TVRD:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Tvardi Therapeutics Inc. has its primary listing on NASDAQ. You can trade Tvardi Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Tvardi Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Tvardi Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Tvardi Therapeutics Inc..